{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T12:20:51Z","timestamp":1754396451759},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T00:00:00Z","timestamp":1548288000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s00280-019-03779-5","type":"journal-article","created":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T23:37:49Z","timestamp":1548373069000},"page":"735-742","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Changes in skeletal muscle area and lean body mass during pazopanib vs sunitinib therapy for metastatic renal cancer"],"prefix":"10.1007","volume":"83","author":[{"given":"Osman","family":"K\u00f6stek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erdem","family":"Y\u0131lmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammet Bekir","family":"Hac\u0131o\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naz\u0131m Can","family":"Demircan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"G\u00f6kyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sernaz","family":"Uzuno\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nermin","family":"Tun\u00e7bilek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0130rfan","family":"\u00c7i\u00e7in","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00fclent","family":"Erdo\u011fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,1,24]]},"reference":[{"issue":"1","key":"3779_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A (2018) Cancer statistics 2018. CA 68(1):7\u201330. \n                    https:\/\/doi.org\/10.3322\/caac.21442","journal-title":"CA"},{"issue":"3","key":"3779_CR2","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1002\/1097-0142(20000801)89:3<604::AID-CNCR16>3.0.CO;2-Q","volume":"89","author":"H Moch","year":"2000","unstructured":"Moch H, Gasser T, Amin MB, Torhorst J, Sauter G, Mihatsch MJ (2000) Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma: a Swiss experience with 588 tumors. Cancer 89(3):604\u2013614","journal-title":"Cancer"},{"key":"3779_CR3","volume-title":"SEER Cancer Statistics Review, 1975\u20132014","author":"N Howlader","year":"2017","unstructured":"Howlader N, Noone A, Krapcho M, Miller D, Bishop K, Kosary C, Yu M, Ruhl J, Tatalovich Z, Mariotto A (2017) SEER Cancer Statistics Review, 1975\u20132014. National Cancer Institute, Bethesda (Based on November 2016 SEER data submission, posted to the SEER web site, April 2017)"},{"issue":"2","key":"3779_CR4","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/wvn.12147","volume":"13","author":"SF Chang","year":"2016","unstructured":"Chang SF, Lin PL (2016) Systematic literature review and meta-analysis of the association of sarcopenia with mortality. Worldviews Evid Based Nurs 13(2):153\u2013162","journal-title":"Worldviews Evid Based Nurs"},{"issue":"1","key":"3779_CR5","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1159\/000484950","volume":"7","author":"KV Chang","year":"2018","unstructured":"Chang KV, Chen JD, Wu WT, Huang KC, Hsu CT, Han DS (2018) Association between loss of skeletal muscle mass and mortality and tumor recurrence in hepatocellular carcinoma: a systematic review and meta-analysis. Liver Cancer 7(1):90\u2013103. \n                    https:\/\/doi.org\/10.1159\/000484950","journal-title":"Liver Cancer"},{"key":"3779_CR6","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ejca.2015.12.030","volume":"57","author":"SS Shachar","year":"2016","unstructured":"Shachar SS, Williams GR, Muss HB, Nishijima TF (2016) Prognostic value of sarcopenia in adults with solid tumours: a meta-analysis and systematic review. Eur J Cancer 57:58\u201367. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2015.12.030","journal-title":"Eur J Cancer"},{"issue":"8","key":"3779_CR7","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1093\/annonc\/mdp605","volume":"21","author":"S Antoun","year":"2010","unstructured":"Antoun S, Baracos VE, Birdsell L, Escudier B, Sawyer MB (2010) Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol 21(8):1594\u20131598. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdp605","journal-title":"Ann Oncol"},{"issue":"1","key":"3779_CR8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1152\/jappl.1998.85.1.115","volume":"85","author":"N Mitsiopoulos","year":"1998","unstructured":"Mitsiopoulos N, Baumgartner RN, Heymsfield SB, Lyons W, Gallagher D, Ross R (1998) Cadaver validation of skeletal muscle measurement by magnetic resonance imaging and computerized tomography. J Appl Physiol (Bethesda Md 1985) 85(1):115\u2013122. \n                    https:\/\/doi.org\/10.1152\/jappl.1998.85.1.115","journal-title":"J Appl Physiol (Bethesda Md 1985)"},{"issue":"5","key":"3779_CR9","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1139\/H08-075","volume":"33","author":"M Mourtzakis","year":"2008","unstructured":"Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE (2008) A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metab 33(5):997\u20131006. \n                    https:\/\/doi.org\/10.1139\/h08-075","journal-title":"Appl Physiol Nutr Metab"},{"issue":"5","key":"3779_CR10","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/bjc.2013.58","volume":"108","author":"O Huillard","year":"2013","unstructured":"Huillard O, Mir O, Peyromaure M, Tlemsani C, Giroux J, Boudou-Rouquette P, Ropert S, Delongchamps NB, Zerbib M, Goldwasser F (2013) Sarcopenia and body mass index predict sunitinib-induced early dose-limiting toxicities in renal cancer patients. Br J Cancer 108(5):1034\u20131041. \n                    https:\/\/doi.org\/10.1038\/bjc.2013.58","journal-title":"Br J Cancer"},{"issue":"1","key":"3779_CR11","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.juro.2015.08.071","volume":"195","author":"H Fukushima","year":"2016","unstructured":"Fukushima H, Nakanishi Y, Kataoka M, Tobisu K, Koga F (2016) Prognostic significance of sarcopenia in patients with metastatic renal cell carcinoma. J Urol 195(1):26\u201332. \n                    https:\/\/doi.org\/10.1016\/j.juro.2015.08.071","journal-title":"J Urol"},{"key":"3779_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10040105","author":"AM Lange","year":"2018","unstructured":"Lange AM, Lo HW (2018) Inhibiting TRK proteins in clinical cancer therapy. Cancers. \n                    https:\/\/doi.org\/10.3390\/cancers10040105","journal-title":"Cancers"},{"issue":"9","key":"3779_CR13","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/nrd2380","volume":"6","author":"S Faivre","year":"2007","unstructured":"Faivre S, Demetri G, Sargent W, Raymond E (2007) Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 6(9):734\u2013745. \n                    https:\/\/doi.org\/10.1038\/nrd2380","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"3779_CR14","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1021\/jm0204183","volume":"46","author":"L Sun","year":"2003","unstructured":"Sun L, Liang C, Shirazian S, Zhou Y, Miller T, Cui J, Fukuda JY, Chu JY, Nematalla A, Wang X, Chen H, Sistla A, Luu TC, Tang F, Wei J, Tang C (2003) Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 46(7):1116\u20131119. \n                    https:\/\/doi.org\/10.1021\/jm0204183","journal-title":"J Med Chem"},{"issue":"1","key":"3779_CR15","first-page":"327","volume":"9","author":"DB Mendel","year":"2003","unstructured":"Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship. Clin Cancer Res 9(1):327\u2013337","journal-title":"Clin Cancer Res"},{"issue":"1","key":"3779_CR16","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1200\/JCO.2005.02.2574","volume":"24","author":"RJ Motzer","year":"2006","unstructured":"Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, Ginsberg MS, Kim ST, Baum CM, DePrimo SE (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin oncol 24(1):16\u201324","journal-title":"J Clin oncol"},{"issue":"21","key":"3779_CR17","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1001\/jama.295.21.2516","volume":"295","author":"RJ Motzer","year":"2006","unstructured":"Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295(21):2516\u20132524","journal-title":"JAMA"},{"issue":"2","key":"3779_CR18","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115\u2013124. \n                    https:\/\/doi.org\/10.1056\/NEJMoa065044","journal-title":"N Engl J Med"},{"issue":"18_suppl","key":"3779_CR19","doi-asserted-by":"publisher","first-page":"5024","DOI":"10.1200\/jco.2007.25.18_suppl.5024","volume":"25","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Figlin RA, Hutson TE, Tomczak P, Bukowski RM, Rixe O, Bjarnason GA, Kim ST, Chen I, Michaelson D (2007) Sunitinib versus interferon-alfa (IFN-\u03b1) as first-line treatment of metastatic renal cell carcinoma (mRCC): updated results and analysis of prognostic factors. J Clin Oncol 25(18_suppl):5024\u20135024. \n                    https:\/\/doi.org\/10.1200\/jco.2007.25.18_suppl.5024","journal-title":"J Clin Oncol"},{"issue":"8","key":"3779_CR20","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1303989","volume":"369","author":"RJ Motzer","year":"2013","unstructured":"Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, Nathan P, Staehler M, de Souza P, Merchan JR, Boleti E, Fife K, Jin J, Jones R, Uemura H, De Giorgi U, Harmenberg U, Wang J, Sternberg CN, Deen K, McCann L, Hackshaw MD, Crescenzo R, Pandite LN, Choueiri TK (2013) Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 369(8):722\u2013731. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1303989","journal-title":"N Engl J Med"},{"key":"3779_CR21","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.critrevonc.2016.08.012","volume":"107","author":"B Rousseau","year":"2016","unstructured":"Rousseau B, Kempf E, Desamericq G, Boissier E, Chaubet-Houdu M, Joly C, Saldana C, Boussion H, Neuzillet C, Macquin-Mavier I (2016) First-line antiangiogenics for metastatic renal cell carcinoma: a systematic review and network meta-analysis. Crit Rev Oncol Hematol 107:44\u201353","journal-title":"Crit Rev Oncol Hematol"},{"issue":"14","key":"3779_CR22","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1200\/JCO.2013.50.8267","volume":"32","author":"B Escudier","year":"2014","unstructured":"Escudier B, Porta C, Bono P, Powles T, Eisen T, Sternberg CN, Gschwend JE, De Giorgi U, Parikh O, Hawkins R, Sevin E, Negrier S, Khan S, Diaz J, Redhu S, Mehmud F, Cella D (2014) Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES study. J Clin Oncol 32(14):1412\u20131418. \n                    https:\/\/doi.org\/10.1200\/jco.2013.50.8267","journal-title":"J Clin Oncol"},{"issue":"3 Pt 1","key":"3779_CR23","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.juro.2016.12.059","volume":"197","author":"MP Laguna","year":"2017","unstructured":"Laguna MP (2017) Re: First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. J Urol 197(3 Pt 1):603. \n                    https:\/\/doi.org\/10.1016\/j.juro.2016.12.059","journal-title":"J Urol"},{"issue":"2","key":"3779_CR24","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s00280-016-3093-8","volume":"78","author":"JH Kim","year":"2016","unstructured":"Kim JH, Park I, Lee JL (2016) Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features. Cancer Chemother Pharmacol 78(2):325\u2013332","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"3779_CR25","first-page":"979","volume":"22","author":"E MacLean","year":"2016","unstructured":"MacLean E, Mardekian J, Cisar LA, Hoang CJ, Harnett J (2016) Real-world treatment patterns and costs for patients with renal cell carcinoma initiating treatment with sunitinib and pazopanib. J Manag Care Spec Pharm 22(8):979\u2013990","journal-title":"J Manag Care Spec Pharm"},{"issue":"18","key":"3779_CR26","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1056\/NEJMc1400731","volume":"370","author":"RJ Motzer","year":"2014","unstructured":"Motzer RJ, Hutson TE, McCann L, Deen K, Choueiri TK (2014) Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med 370(18):1769\u20131770","journal-title":"N Engl J Med"},{"issue":"3","key":"3779_CR27","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.eururo.2016.11.020","volume":"71","author":"S Fernandez-Pello","year":"2017","unstructured":"Fernandez-Pello S, Hofmann F, Tahbaz R, Marconi L, Lam TB, Albiges L, Bensalah K, Canfield SE, Dabestani S, Giles RH, Hora M, Kuczyk MA, Merseburger AS, Powles T, Staehler M, Volpe A, Ljungberg B, Bex A (2017) A systematic review and meta-analysis comparing the effectiveness and adverse effects of different systemic treatments for non-clear cell renal cell carcinoma. Eur Urol 71(3):426\u2013436. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2016.11.020","journal-title":"Eur Urol"},{"issue":"1","key":"3779_CR28","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/nrd4467","volume":"14","author":"S Cohen","year":"2015","unstructured":"Cohen S, Nathan JA, Goldberg AL (2015) Muscle wasting in disease: molecular mechanisms and promising therapies. Nat Rev Drug Discov 14(1):58\u201374. \n                    https:\/\/doi.org\/10.1038\/nrd4467","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"3779_CR29","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1097\/MOU.0000000000000207","volume":"25","author":"M Schmidinger","year":"2015","unstructured":"Schmidinger M, Wittes J (2015) First-line treatment of metastatic renal cell carcinoma after COMPARZ and PISCES. Curr Opin Urol 25(5):395\u2013401. \n                    https:\/\/doi.org\/10.1097\/mou.0000000000000207","journal-title":"Curr Opin Urol"},{"issue":"3","key":"3779_CR30","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s41419-018-0388-1","volume":"9","author":"P Makhov","year":"2018","unstructured":"Makhov P, Naito S, Haifler M, Kutikov A, Boumber Y, Uzzo RG, Kolenko VM (2018) The convergent roles of NF-kappaB and ER stress in sunitinib-mediated expression of pro-tumorigenic cytokines and refractory phenotype in renal cell carcinoma. Cell Death Dis 9(3):374. \n                    https:\/\/doi.org\/10.1038\/s41419-018-0388-1","journal-title":"Cell Death Dis"},{"issue":"3","key":"3779_CR31","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1615\/CritRevOncog.v17.i3.30","volume":"17","author":"JM Argiles","year":"2012","unstructured":"Argiles JM, Lopez-Soriano FJ, Busquets S (2012) Counteracting inflammation: a promising therapy in cachexia. Crit Rev Oncog 17(3):253\u2013262. \n                    https:\/\/doi.org\/10.1615\/CritRevOncog.v17.i3.30","journal-title":"Crit Rev Oncog"},{"issue":"3","key":"3779_CR32","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s13539-012-0074-6","volume":"3","author":"A Fanzani","year":"2012","unstructured":"Fanzani A, Conraads VM, Penna F, Martinet W (2012) Molecular and cellular mechanisms of skeletal muscle atrophy: an update. J Cachexia Sarcopenia Muscle 3(3):163\u2013179","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"11","key":"3779_CR33","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.22034\/APJCP.2017.18.11.2977","volume":"18","author":"LV Spirina","year":"2017","unstructured":"Spirina LV, Usynin EA, Yurmazov ZA, Slonimskaya EM, Kondakova IV (2017) Effect of targeted therapy with pazopanib on expression levels of transcription, growth factors and components of AKT\/m-TOR signaling pathway in patients with renal cell carcinoma. Asian Pac J Cancer Prev 18(11):2977\u20132983. \n                    https:\/\/doi.org\/10.22034\/APJCP.2017.18.11.2977","journal-title":"Asian Pac J Cancer Prev"},{"issue":"3","key":"3779_CR34","doi-asserted-by":"publisher","first-page":"103","DOI":"10.5387\/fms.2018-15","volume":"64","author":"K Ishibashi","year":"2018","unstructured":"Ishibashi K, Koguchi T, Matsuoka K, Onagi A, Tanji R, Takinami-Honda R, Hoshi S, Onoda M, Kurimura Y, Hata J, Sato Y, Kataoka M, Ogawsa S, Haga N, Kojima Y (2018) Interleukin-6 induces drug resistance in renal cell carcinoma. Fukushima J Med Sci 64(3):103\u2013110. \n                    https:\/\/doi.org\/10.5387\/fms.2018-15","journal-title":"Fukushima J Med Sci"},{"issue":"8","key":"3779_CR35","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/S1470-2045(12)70241-3","volume":"13","author":"HT Tran","year":"2012","unstructured":"Tran HT, Liu Y, Zurita AJ, Lin Y, Baker-Neblett KL, Martin AM, Figlin RA, Hutson TE, Sternberg CN, Amado RG, Pandite LN, Heymach JV (2012) Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol 13(8):827\u2013837. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(12)70241-3","journal-title":"Lancet Oncol"},{"issue":"2","key":"3779_CR36","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.clgc.2012.09.006","volume":"11","author":"C Carmichael","year":"2013","unstructured":"Carmichael C, Yuh BE, Sun V, Lau C, Hsu J, Saikia J, Liu X, Wilson T, Ferrell B, Pal SK (2013) Quality of life in patients with metastatic renal cell carcinoma: assessment of long-term survivors. Clin Genitourin Cancer 11(2):149\u2013154","journal-title":"Clin Genitourin Cancer"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-019-03779-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03779-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03779-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,1,23]],"date-time":"2020-01-23T19:09:10Z","timestamp":1579806550000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-019-03779-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,24]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["3779"],"URL":"https:\/\/doi.org\/10.1007\/s00280-019-03779-5","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,24]]},"assertion":[{"value":"18 August 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}